BMS agrees deal worth up to $1.56bn for Agenus’ TIGIT cancer drugBristol-Myers Squibb has paid $200 million, and promised up to $1.36 billion in “biobucks” for exclusive rights to Share XBMS agrees deal worth up to $1.56bn for Agenus’ TIGIT cancer drughttps://pharmaphorum.com/news/bms-agrees-deal-worth-up-to-1-56bn-for-agenus-tigit-cancer-drug/
